Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Treace Medical Concepts (TMCI) over the last 6 years, with Q3 2025 value amounting to -$10000.0.

  • Treace Medical Concepts' Cash from Financing Activities fell 22500.0% to -$10000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $721000.0, marking a year-over-year increase of 14113.71%. This contributed to the annual value of $160000.0 for FY2024, which is 9985.37% down from last year.
  • According to the latest figures from Q3 2025, Treace Medical Concepts' Cash from Financing Activities is -$10000.0, which was down 22500.0% from $987000.0 recorded in Q2 2025.
  • Treace Medical Concepts' 5-year Cash from Financing Activities high stood at $107.9 million for Q1 2023, and its period low was -$1.2 million during Q1 2021.
  • Its 5-year average for Cash from Financing Activities is $12.6 million, with a median of $297000.0 in 2022.
  • Per our database at Business Quant, Treace Medical Concepts' Cash from Financing Activities crashed by 379393.94% in 2021 and then skyrocketed by 776290.09% in 2023.
  • Quarter analysis of 5 years shows Treace Medical Concepts' Cash from Financing Activities stood at $1.0 million in 2021, then plummeted by 71.05% to $297000.0 in 2022, then plummeted by 44.44% to $165000.0 in 2023, then tumbled by 84.24% to $26000.0 in 2024, then crashed by 138.46% to -$10000.0 in 2025.
  • Its Cash from Financing Activities stands at -$10000.0 for Q3 2025, versus $987000.0 for Q2 2025 and -$282000.0 for Q1 2025.